Cas No.: | 211735-76-1 |
Chemical Name: | CX-691; Org2444;CX691;CX 691 |
Synonyms: | CX-691; Org2444;CX691;CX 691 |
SMILES: | O=C(N1CCCCC1)C2=CC3=NON=C3C=C2 |
Formula: | C12H13N3O2 |
M.Wt: | 231.25 |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Farampator (CX-691;Org24448) is an AMPA receptor positive modulator. |
In Vivo: | Farampator has potential in treating disorders characterised by cognitive deficits such as Alzheimer's disease and schizophrenia. CX691 attenuates a scopolamine-induced impairment of cued fear conditioning following acute administration (0.1 mg/kg p.o.) and a temporally induced deficit in novel object recognition following both acute (0.1 and 1.0 mg/kg p.o.) and sub-chronic (bi-daily for 7 days) administration (0.01, 0.03, 0.1 mg/kg p.o.). It also improves attentional set-shifting following sub-chronic administration (0.3 mg/kg p.o.)[1]. Farampator (500 mg) unequivocally improves short-term memory but appeares to impair episodic memory. Furthermore, it tends to decrease the number of switching errors in the CTMT. Drug-induced side effects (SEs) included headache, somnolence and nausea. Subjects with SEs has significantly higher plasma levels of farampator than subjects without SEs[2]. |